RxDoctor Payments Data

Amy Korwin, MD

Pulmonary Disease · New Britain, CTNPI 1619387818

Payments from drug & device makers

$943in general payments, 2019–2025

Across 32 payments — averaging $29.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$549
  • GSK$217
  • Harmony Biosciences LLC$67
  • Mylan Specialty L.p.$46
  • Regeneron Healthcare Solutions, Inc.$34
  • Amgen$31

What the payments were for

  • Food & beverage$88894%
  • Education$556%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$943 in reported general payments places this provider in the 40th percentile of 255 pulmonary disease providers in Connecticut.

See all pulmonary disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$21,512
Medicare patients
114
Services billed
264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter298$238,930
Breo ElliptaFluticasone/Vilanterol87$37,796
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr65$37,761
Breztri AerosphereBudesonide/Glycopyr/Formoterol30$19,205
Stiolto RespimatTiotropium Br/Olodaterol Hcl19$9,172
Spiriva HandihalerTiotropium Bromide13$8,414
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate45$5,693
Albuterol Sulfate HfaAlbuterol Sulfate254$4,403
SymbicortBudesonide/Formoterol Fumarate13$3,416
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$3,201
Wixela InhubFluticasone Propion/Salmeterol16$1,876
Ventolin HfaAlbuterol Sulfate30$1,570
Mometasone Furoate13$1,463
Montelukast Sodium76$596
Azelastine Hcl24$323

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$217$314,488450 claims
AstraZenecaBreztri Aerosphere, Symbicort$549$22,62043 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 255 pulmonary disease providers in Connecticut.

Other pulmonary disease in New Britain

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →